Finance Watch: 3T Biosciences Emerges With $40m And Novel TCR Platform informa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from informa.com Daily Mail and Mail on Sunday newspapers.
Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to a particular destination in the body while the second tells the therapy what to do once it gets there. With the Series C financing, Senda aims to reach the clinic in 2024.
/PRNewswire/ Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the completion.